March 14, 2020, at Robertson Life Sciences Building
About the colloquium
Hosted by the OHSU Brain Institute, this full-day CME course will explore both basic and advanced diagnosis and management challenges in neuromuscular disorders. National and international experts in the field of neuromuscular medicine will present engaging lectures aimed at fine-tuning one's skills in evaluating patients with myopathy, peripheral neuropathy and neuromuscular junction disorders. Updates in the latest neuromuscular research as well as challenging cases will be explored and discussed. We invite registered attendees to submit their most challenging or undiagnosed cases for case studies and panel discussion.
Who should attend
Neurologists, rheumatologists, physiatrists, internal medicine and family medicine physicians, physician assistants, nurse practitioners and others who treat or manage patients with a neuromuscular disorder.
7-8:15 a.m.: Registration and breakfast
8:15-8:30 a.m.: Welcome – Chafic Karam
8:30-9 a.m.: Disorders of Neuromuscular Transmission – Vern Juel
9-9:30 a.m.: Approach to POTS and Dysautonomia – Safwan Jaradeh
9:30-10 a.m.: The role of placebo in neuromuscular health and clinical trials – Aziz Shaibani
10-10:15 a.m.: Break
10:15-10:50 a.m.: Myositis Mimics – Colin Quinn
10:50-11:20 a.m.: Is there still a role for muscle biopsies in 2020? – Amir Sabouri
11:20-11:50 a.m.: Role of antibody testing in NM disorders – Nizar Chahin
11:50 a.m.-1 p.m.: Lunch break
1-2 p.m.: Case discussion – Thomas Ragole
2-3 p.m.: Mis-Diagnosis and Over-treatment of CIDP: The Fault Lies with the Variants – Richard Lewis
3-3:15 p.m.: Break
3:15-4 p.m.: Recent Advances in ALS and new promising therapies – John Ravits
4-4:30 p.m.: Neuromuscular Clinical trials at OHSU – Chafic Karam
4:30 p.m.: Closing remarks
- Review the clinical presentation and salient findings in selected neuromuscular transmission disorders including myasthenia gravis, discuss diagnostic strategies in potential NMT disorders including use of electrodiagnostic and serological studies, survey management strategies for confirmed NMT disorders.
- Describe the importance of placebo in treating neuromuscular disorders.
- Explain the biology and neuroscience of the placebo effect.
- Explain the factors that contribute to the placebo response in clinical trials.
- Explain how to manipulate the placebo effect.
- Scientifically describe the role of empathy and expectations in the healing process response to treatment.
- Review an approach to non-myopathy mimics of myositis, discuss case examples of non-myopathy mimics of myositis, review myopathy mimics of (treatable) myositis.
- Discuss case examples of myopathy mimics of (treatable) myositis.
- Discuss clinical scenarios where a muscle biopsy is no longer required, discuss clinical scenarios where a muscle biopsy is indispensable, introduce a highly effective systematic interdisciplinary approach to the diagnosis of myopathies.
- Recognize the important clinical features of CIDP.
- Explain an approach that can determine when an atypical presentation is a variant of CIDP.
- Recognize the pitfalls that can lead to mis-diagnosis.
- Develop a treatment plan that optimize therapeutic benefit.
- Describe the relationship of ALS and frontotemporal dementia at the clinical, genetic and neuropathologic level.
- Explain the importance of repeat expansions in C9orf72.
- Describe antisense oligonucleotides and their therapeutic potential in ALS and related neurodegnerations.
- Describe clinical testing and pipeline of approaches to therapy.
- Discuss ongoing neuromuscular studies at OHSU.
- $120 registration until March 1, 2020
- $150 March 2-14, 2020
Residence Inn Portland Downtown/Riverplace
2115 S.W. River Parkway
Portland, OR 97201
In accordance with the requirements of the Standards for Commercial Support of the Accreditation Council for Continuing Medical Education, each instructor and member of the planning committee has disclosed any relevant financial relationships with commercial interests.